絲路視覺(300556.SZ):股東丁鵬青及田萬軍擬分別減持7.06萬股及5.95萬股
格隆匯6月8日丨絲路視覺(300556.SZ)公佈,持有公司股份282,421股(佔公司總股本比例0.23%)的董事、高級副總裁丁鵬青擬自公告披露之日起15個交易日後的3個月內(2025年6月30日至2025年9月29日,窗口期不減持)以集中競價方式減持公司股份不超70,600股(佔公司總股本比例0.058%)。
持有公司股份238,050股(佔公司總股本比例0.20%)的副總裁田萬軍擬自公告披露之日起15個交易日後的3個月內(2025年6月30日至2025年9月29日,窗口期不減持)以集中競價方式減持公司股份不超59,500股(佔公司總股本比例0.049%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.